Boston Scientific/Schneider
This article was originally published in The Gray Sheet
Executive Summary
Waiting period under the Hart-Scott-Rodino Act for the $2.1 bil. cash acquisition of Pfizer's Schneider unit by Boston Scientific expires on July 31, Pfizer reports ("The Gray Sheet" June 22, p. 2). For the three months ended June 30, Boston Scientific reports net income of $79 mil. compared to $90 mil. in the second quarter of 1997 (exclusive of special charges). Revenues are up 7% during the period to $506 mil